He lost half his vision to glaucoma. Now he's using AI to help spot disease — but he says tech will never replace doctors.
The diagnosis sparked the start of his healthtech startup, which uses AI to detect critical diseases.
Choi said AI can speed up and simplify screening, but it's no substitute for a doctor.
At 26, Kevin Choi got a diagnosis that changed his life: glaucoma.
It's a progressive eye disease that damages the optic nerve, often without symptoms until it's too late. By the time doctors caught it, Choi had lost half his vision.
An engineer by training — and a former rifleman in South Korea's Marine Corps — Choi thought he had a solid handle on his health.
"I was really frustrated I didn't notice that," he said.
The 2016 diagnosis still gives him "panic." But it also sparked something big.
That year, Choi teamed up with his doctor, a vitreoretinal surgeon, to cofound Mediwhale, a South Korea-based healthtech startup.
Their mission is to use AI to catch diseases before symptoms show up and cause irreversible harm.
"I'm the person who feels the value of that the most," Choi said.
The tech can screen for cardiovascular, kidney, and eye diseases through non-invasive retinal scans.
Mediwhale's technology is primarily used in South Korea, and hospitals in Dubai, Italy, and Malaysia have also adopted it.
Mediwhale said in September that it had raised $12 million in its Series A2 funding round, led by Korea Development Bank.
Choi believes AI is most powerful in the earliest stage of care: screening.
AI, he said, can help healthcare providers make faster, smarter decisions — the kind that can mean the difference between early intervention and irreversible harm.
In some conditions, "speed is the most important," Choi said. That's true for "silent killers" like heart and kidney disease, and progressive conditions like glaucoma — all of which often show no early symptoms but, unchecked, can lead to permanent damage.
For patients with chronic conditions like diabetes or obesity, the stakes are even higher. Early complications can lead to dementia, liver disease, heart problems, or kidney failure.
The earlier these risks are spotted, the more options doctors — and patients — have.
Choi said Mediwhale's AI makes it easier to triage by flagging who's low-risk, who needs monitoring, and who should see a doctor immediately.
Screening patients at the first point of contact doesn't require "very deep knowledge," Choi said. That kind of quick, low-friction risk assessment is where AI shines.
Mediwhale's tool lets patients bypass traditional procedures — including blood tests, CT scans, and ultrasounds — when screening for cardiovascular and kidney risks.
Choi also said that when patients see their risks visualized through retinal scans, they tend to take it more seriously.
Despite his belief in AI's power, Choi is clear: It's not a replacement for doctors.
Patients want to hear a human doctor's opinion and reassurance.
Choi also said that medicine is often messier than a clean dataset. While AI is "brilliant at solving defined problems," it lacks the ability to navigate nuance.
"Medicine often requires a different dimension of decision-making," he said.
For example: How will a specific treatment affect someone's life? Will they follow through? How is their emotional state affecting their condition? These are all variables that algorithms still struggle to read, but doctors can pick up. These insights "go beyond simple data points," Choi said.
And when patients push back — say, hesitating to start a new medication — doctors are trained to both understand why and guide them.
They are able to "navigate patients' irrational behaviours while still grounding decisions in quantitative data," he said.
"These are complex decision-making processes that extend far beyond simply processing information."
Read the original article on Business Insider

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
27 minutes ago
- Associated Press
KindlyMD Closes $200 Million Convertible Note Offering
Company Intends to Use Net Proceeds to Fund Purchase of Bitcoin and for General Corporate Purposes Follows the Completion of KindlyMD's Merger with Nakamoto to Form Institutional-Grade Bitcoin Treasury Vehicle SALT LAKE CITY, UT / ACCESS Newswire / August 15, 2025 / KindlyMD, Inc. (NASDAQ:NAKA) ('KindlyMD' or the 'Company'), a provider of integrated healthcare services and institutional-grade Bitcoin treasury vehicle, today announced that it has closed its previously announced offering of a senior secured convertible note in an aggregate principal amount of $200.0 million (the 'Convertible Note') in a private offering to YA II PN, Ltd., an investment fund managed by Yorkville Advisors ('YA II'). The closing of this Convertible Note offering follows the completion of KindlyMD's strategic combination with Nakamoto Holdings Inc. ('Nakamoto'), a Bitcoin-native holding company. The Company intends to use the net proceeds from the Convertible Note offering to purchase more Bitcoin, as well as for working capital and general corporate purposes. The issuance of the Convertible Note further expands the Company's Bitcoin treasury strategy and adds to the $540 million of gross proceeds from a private placement in public equity ('PIPE Financing'), which closed concurrently with the Company's combination with Nakamoto. David Bailey, Chief Executive Officer and Chairman of KindlyMD, said, 'The strong support we continue to receive from investors is validation of our pioneering Bitcoin treasury strategy. We are excited to leverage our enhanced balance sheet and differentiated go-to-market strategy to acquire as much Bitcoin as possible.' The Convertible Note bears interest at a rate of 0.00% per annum for the first two years, and 6.00% per annum for the third year and is payable on August 15, 2028, the third-year anniversary of the issuance date of the Convertible Debenture or earlier redemption date. The Convertible Note provides that YA II may convert all or any portion of the principal amount of the Convertible Note, together with any accrued and unpaid interest thereon, at an initial conversion price of $2.80, which is subject to adjustment and a floor price and maximum number of convertible shares of the Company's common stock. The Company also has the right to redeem the Convertible Note under certain circumstances. Advisors Cohen & Company Capital Markets ('CCM'), a division of Cohen & Company Securities, LLC served as lead financial advisor to Nakamoto and placement agent for the PIPE Financing. 10X Capital ('10X'), through its affiliated broker-dealer, also served as a financial advisor and placement agent. Reed Smith LLP and Holland & Hart LLP acted as legal advisor to KindlyMD. About KindlyMD KindlyMD® is a patient-first healthcare company integrating traditional primary care, pain management, behavioral health, and alternative therapies to provide comprehensive, whole-person care. In August 2025, KindlyMD completed its merger with Nakamoto Holdings Inc., a Bitcoin-native holding company, to establish a publicly traded Bitcoin treasury vehicle. This strategic combination unites KindlyMD's healthcare expertise with Nakamoto's vision of integrating Bitcoin into global capital markets, creating a diversified entity focused on both healthcare innovation and Bitcoin treasury management. For more information, please visit Forward-Looking Statements All statements, other than statements of historical fact, included in this press release that address activities, events or developments that that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements, as defined under U.S. federal securities laws, related to KindlyMD. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and often include statements about our future operations, business strategies, plans, objectives, expectations, intentions, goals, projections, prospects, future events, or performance, as well as underlying assumptions. These statements-covering matters such as expectations, plans, strategic outlooks, financial projections, market conditions, regulatory environments, Bitcoin-related strategies, Bitcoin treasury management activities, and KindlyMD's anticipated holding of Bitcoin as part of its corporate treasury are inherently uncertain and involve numerous assumptions and risks. Forward-looking terms used may include, but are not limited to, 'estimate,' 'project,' 'predict,' 'believe,' 'expect,' 'anticipate,' 'potential,' 'create,' 'intend,' 'could,' 'would,' 'may,' 'plan,' 'will,' 'guidance,' 'look,' 'goal,' 'future,' 'build,' 'focus,' 'continue,' 'strive,' 'allow,' 'seek,' 'aim,' 'target,' or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements and similar expressions. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to, descriptions of KindlyMD and its operations, strategies and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, including the purchase, custody, and potential sale or other use of Bitcoin, synergies, opportunities and anticipated future performance, including the management team and board of directors of KindlyMD. These statements may also relate to broader macroeconomic trends, industry developments, technology adoption, competitive positioning, market expansion, product launches, research and development efforts, acquisitions or dispositions, legal or regulatory developments, and other initiatives that could affect our future business performance. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. These include risks relating to Bitcoin market volatility, cybersecurity and custody of digital assets, potential changes in laws or accounting standards relating to cryptocurrency, and regulatory developments affecting Bitcoin or other digital assets, as well as the risk that changes in KindlyMD's capital structure and governance could have adverse effects on the market value of its securities; the ability of KindlyMD to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on KindlyMD operating results and business generally; the risk that KindlyMD may be unable to reduce expenses or access financing or liquidity; the impact of any related economic downturn; the risk of changes in governmental regulations or enforcement practices; adverse impacts from geopolitical events, health crises, supply chain disruptions, changes to laws or accounting standards, cybersecurity threats or data breaches, intellectual property disputes, competitive pressures, or changes in consumer behavior; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond KindlyMD's control, including those detailed in KindlyMD's Annual Reports on Form 10-K, Quarterly Reports on Form 10- Q, Current Reports on Form 8-K, and such other documents of KindlyMD filed, or to be filed, with the SEC that are or will be available on KindlyMD's website at and on the website of the SEC at All forward-looking statements are based on assumptions that KindlyMD believes to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and KindlyMD does not undertake any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Nothing contained herein constitutes an offer to buy or sell securities of KindlyMD or any other party, nor does it constitute a solicitation of any proxy or vote. Contacts Media Carissa Felger / Sam Cohen Gasthalter & Co. Phone: (212) 257-4170 Email: [email protected] Investors Valter Pinto, Managing Director KCSA Strategic Communications Phone: (212) 896-1254 Email: [email protected] SOURCE: KindlyMD, Inc press release

Wall Street Journal
27 minutes ago
- Wall Street Journal
Dow Industrials Hit First Intraday High of 2025, Powered by UnitedHealth Shares
A major rally in UnitedHealth UNH 11.98%increase; green up pointing triangle Group stock propelled the Dow Jones Industrial Average to its first intraday record of 2025. UnitedHealth, the Dow's biggest laggard since early April, jumped 12% on Friday after a filing showed that Warren Buffett's Berkshire Hathaway BRK.B -0.42%decrease; red down pointing triangle took a roughly $1.6 billion position in the healthcare company during the second quarter. UnitedHealth stock remains down 40% for the year.
Yahoo
2 hours ago
- Yahoo
Warren Buffett Is Betting Big on UnitedHealth Stock. Should You?
UnitedHealth (UNH) shares soared as much as 14% on Friday after a regulatory filing confirmed legendary investor Warren Buffett has built a nearly $1.6 billion stake in the beleaguered healthcare giant. Buffett's conglomerate Berkshire Hathaway (BRK.A) (BRK.B) now owns about 5 million UNH shares in total. Other high-profile names that have capitalized on UnitedHealth's crash this year include 'Big Short' investor Michael Burry and David Tepper, the founder of Appaloosa Management. More News from Barchart UnitedHealth Stock Soars as Warren Buffett's Berkshire Hathaway Discloses $1.57B Stake Palantir CEO Alex Karp Sees More Gains Ahead With America-Focused Growth Strategy, Calls U.S. The 'Leader of the Free World' Lucid Motors Is Caught in a Tariff Trap. Is LCID Stock More Likely to Hit $1 or $7 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Including today's surge, UnitedHealth stock is up roughly 30% versus its year-to-date low set in early August. Compared to its share price on April 11, however, it's still down nearly 50%. What Buffett's Stake Mean for UnitedHealth Stock Buffett's $1.6 billion stake is massively constructive for UNH stock as it signals conviction in the insurer's long-term value despite its recent struggles. The 'Oracle of Omaha' has reputation for disciplined, value-driven investing, which often boosts market confidence, attracts institutional interest, and stabilizes sentiment. Plus, sizable investments from other notable investors like Burry and Tepper reinforces the narrative that UnitedHealth shares are undervalued, potentially poised for recovery. Their collective endorsement is a huge vote of confidence in the company's fundamentals, business model, and resilience, driving renewed investor optimism and upward momentum in the stock. Should You Invest in UNH Shares at Current Levels Buffett's investment may be a reason to load up on UnitedHealth stock also because 'it's available at a 50% discount,' according to a renowned professor at the University of Maryland, David Kass. Kass agrees that UNH will see 'major fines' and the NYSE-listed behemoth will have to fire some executives, but said longer term, 'the company will survive and likely regain its prominence in the industry.' He recommends owning UNH shares at current levels also because it offers robust finances, above-average profitability and 'a below average price-to-earnings (P/E) ratio.' A healthy 2.9% dividend yield makes up for another great reason to buy UnitedHealth stock here. UnitedHealth Remains a 'Buy'-Rated Stock Investors should also note that Wall Street hasn't entirely turned its back on UnitedHealth stock. The consensus rating on UNH shares currently sits at 'Moderate Buy' with price targets going as high as $440, indicating potential upside of another 42% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data